Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M

28Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Protein kinase CK2 has diverse functions promoting and maintaining cancer phenotypes. We investigated the effect of CK2 inhibition in lung cancer cells with T790M-mediated resistance to the EGFR-TK inhibitor. Resistant sublines of PC-9 to gefitinib (PC-9/GR) and erlotinib (PC-9/ER) were established by previous study, and T790M secondary mutation was found in both resistant sublines. A decrease of EGFR by siRNA treatment effectively controlled the growth of resistant cells, thus suggesting that they still have EGFR-dependency. CX-4945, a potent and selective CK2 inhibitor, induced autophagy in PC-9/GR and PC-9/ER, and which was supported by the induction of autophagic vacuoles and microtubule-associated protein 1 light chain 3 (LC3) expression, and the increase of punctate fluorescent signals in resistant cells pre-transfected with green fluorescent protein (GFP)-tagged LC3. However, the withdrawal of CX-4945 led to the recovery of cancer cells with autophagy. We found that the induction of autophagy by CX-4945 in both resistant cells was CK2 dependent by using small interfering RNA against CK2. The treatment with CX-4945 alone induced a minimal growth inhibition in resistant cells. However, combined treatment of CX-4945 and EGFR-TKI effectively inhibited cancer-cell proliferation and induced apoptosis. CX-4945 increased the translocation of EGFR from the cell surface into the autophagosome, subsequently leading to the decrease of EGFR while inhibition of autophagy by 3MA or Atg7-targeted siRNA pretreatment reduced the decrease of EGFR by CX-4945. Accordingly, apoptosis by a combination of CX-4945 and EGFR-TKI was suppressed by 3MA or Atg7-targeted siRNA pretreatment, thus suggesting that autophagosome-mediated EGFR down-regulation would have an important role regarding apoptotic cell death by EGFR-TKI. Combined treatment of the CK2 inhibitor and EGFR-TKI may be a promising strategy for overcoming T790M-mediated resistance.

References Powered by Scopus

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

7614Citations
N/AReaders
Get full text

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

4938Citations
N/AReaders
Get full text

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

3733Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cell death-based treatment of lung adenocarcinoma article

541Citations
N/AReaders
Get full text

Role of protein kinase CK2 in antitumor drug resistance

83Citations
N/AReaders
Get full text

EGFR family members’ regulation of autophagy is at a crossroads of cell survival and death in cancer

81Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

So, K. S., Kim, C. H., Rho, J. K., Kim, S. Y., Choi, Y. J., Song, J. S., … Lee, J. C. (2014). Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M. PLoS ONE, 9(12). https://doi.org/10.1371/journal.pone.0114000

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

62%

Researcher 6

23%

Professor / Associate Prof. 3

12%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

38%

Biochemistry, Genetics and Molecular Bi... 7

29%

Agricultural and Biological Sciences 6

25%

Chemistry 2

8%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free